Patents by Inventor Andreas Gollner

Andreas Gollner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210101912
    Abstract: The present invention encompasses compounds of formula (I) wherein the groups R1 to R7, A, V, W, X, Y, n, r and q are defined in claim 1, their use as inhibitors of MDM2-p53 interaction, pharmaceutical compositions which contain compounds of this kind, their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases, and synthetic intermediates.
    Type: Application
    Filed: December 11, 2020
    Publication date: April 8, 2021
    Inventors: Juergen RAMHARTER, Joachim BROEKER, Annika GILLE, Andreas GOLLNER, Manuel HENRY, Nina KERRES, Harald WEINSTABL
  • Patent number: 10919913
    Abstract: The present invention encompasses compounds of formula (I) wherein the groups R1 to R7, A, V, W, X, Y, n, r and q are defined in claim 1, their use as inhibitors of MDM2-p53 interaction, pharmaceutical compositions which contain compounds of this kind, their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases, and synthetic intermediates.
    Type: Grant
    Filed: February 11, 2019
    Date of Patent: February 16, 2021
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Juergen Ramharter, Joachim Broeker, Annika Gille, Andreas Gollner, Manuel Henry, Nina Kerres, Harald Weinstabl
  • Patent number: 10882866
    Abstract: The present invention encompasses intermediates for preparing compounds of formula (I) wherein the groups R1 to R4, R7, A, D, E, F, V, W, X, Y, n, r and q are defined in claim 1, their use as inhibitors of MDM2-p53 interaction, pharmaceutical compositions which contain compounds of this kind, their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases, and synthetic intermediates.
    Type: Grant
    Filed: April 9, 2020
    Date of Patent: January 5, 2021
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Andreas Gollner, Joachim Broeker, Nina Kerres, Christiane Kofink, Juergen Ramharter, Harald Weinstabl, Annika Gille, Stefan Goepper, Manuel Henry, Guenther Huchler
  • Patent number: 10717742
    Abstract: The present invention encompasses compounds of formula (I) wherein the groups R1 to R4, R7, A, D, E, F, V, W, X, Y, n, r and q are defined in claim 1, their use as inhibitors of MDM2-p53 interaction, pharmaceutical compositions which contain compounds of this kind, their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases, and synthetic intermediates.
    Type: Grant
    Filed: June 8, 2018
    Date of Patent: July 21, 2020
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Andreas Gollner, Joachim Broeker, Nina Kerres, Christiane Kofink, Juergen Ramharter, Harald Weinstabl, Annika Gille, Stefan Goepper, Manuel Henry, Guenther Huchler
  • Patent number: 10695334
    Abstract: Heteroaromatic carboxamides of formula (I), wherein Y, R, and X are as defined herein, and pharmaceutically acceptable salts thereof. The compounds of formula (I) can be used in methods for the treatment of diseases which can be influenced by inhibition of plasma kallikrein.
    Type: Grant
    Filed: August 14, 2019
    Date of Patent: June 30, 2020
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Matthias Eckhardt, Andreas Gollner, Elke Langkopf, Holger Wagner, Dieter Wiedenmayer
  • Patent number: 10576064
    Abstract: The present invention relates to compounds of formula (I) wherein the groups R1 to R3, R7, U, V, W, X, Y, n and q are as defined herein, their use as inhibitors of MDM2-p53 interaction, pharmaceutical compositions which contain compounds of this kind, their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases and synthetic intermediates.
    Type: Grant
    Filed: July 2, 2015
    Date of Patent: March 3, 2020
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Harald Weinstabl, Andreas Gollner, Juergen Ramharter, Tobias Wunberg
  • Publication number: 20200054617
    Abstract: Heteroaromatic carboxamides of formula (I), wherein Y, R, and X are as defined herein, and pharmaceutically acceptable salts thereof. The compounds of formula (I) can be used in methods for the treatment of diseases which can be influenced by inhibition of plasma kallikrein.
    Type: Application
    Filed: August 14, 2019
    Publication date: February 20, 2020
    Inventors: Matthias ECKHARDT, Andreas GOLLNER, Elke LANGKOPF, Holger WAGNER, Dieter WIEDENMAYER
  • Patent number: 10501440
    Abstract: Disclosed are heteroarylcarboxamides of formula (I), and pharmaceutically acceptable salts thereof, wherein A, T, R1, R2 and R3 are as defined herein. Also disclosed are methods of using these compounds for the treatment of diseases which can be influenced by inhibition of plasma kallikrein.
    Type: Grant
    Filed: April 16, 2018
    Date of Patent: December 10, 2019
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Sara Frattini, Iain Lingard, Dieter Wolfgang Hamprecht, Remko Alexander Bakker, Matthias Eckhardt, Andreas Gollner, Joerg P. Hehn, Elke Langkopf, Holger Wagner, Bernd Wellenzohn, Dieter Wiedenmayer
  • Publication number: 20190169209
    Abstract: The present invention encompasses compounds of formula (I) wherein the groups R1 to R7, A, V, W, X, Y, n, r and q are defined in claim 1, their use as inhibitors of MDM2-p53 interaction, pharmaceutical compositions which contain compounds of this kind, their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases, and synthetic intermediates.
    Type: Application
    Filed: February 11, 2019
    Publication date: June 6, 2019
    Inventors: Juergen RAMHARTER, Joachim BROEKER, Annika GILLE, Andreas GOLLNER, Manuel HENRY, Nina KERRES, Harald WEINSTABL
  • Patent number: 10246467
    Abstract: The present invention encompasses compounds of formula (I) wherein the groups R1 to R7, A, V, W, X, Y, n, r and q are defined in claim 1, their use as inhibitors of MDM2-p53 interaction, pharmaceutical compositions which contain compounds of this kind, their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases, and synthetic intermediates.
    Type: Grant
    Filed: August 20, 2015
    Date of Patent: April 2, 2019
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Juergen Ramharter, Joachim Broeker, Annika Gille, Andreas Gollner, Manuel Henry, Nina Kerres, Harald Weinstabl
  • Patent number: 10144739
    Abstract: The present invention encompasses compounds of formula (I) wherein the groups R1 to R4, R7, A, D, E, F, V, W, X, Y, n, r and q are defined in claim 1, their use as inhibitors of MDM2-p53 interaction, pharmaceutical compositions which contain compounds of this kind, their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases, and synthetic intermediates.
    Type: Grant
    Filed: October 7, 2016
    Date of Patent: December 4, 2018
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Andreas Gollner, Joachim Broeker, Nina Kerres, Christiane Kofink, Juergen Ramharter, Harald Weinstabl
  • Patent number: 10138251
    Abstract: The present invention encompasses compounds of formula (I) wherein the groups R1 to R7, V, W, X, Y, n and q are defined herein, their use as inhibitors of MDM2-p53 interaction, pharmaceutical compositions which contain compounds of this kind, their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases and synthetic intermediates.
    Type: Grant
    Filed: April 10, 2015
    Date of Patent: November 27, 2018
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Andreas Gollner, Christiane Kofink, Juergen Ramharter, Harald Weinstabl, Tobias Wunberg
  • Publication number: 20180305339
    Abstract: Disclosed are heteroarylcarboxamides of formula (I), and pharmaceutically acceptable salts thereof, wherein A, T, R1, R2 and R3 are as defined herein. Also disclosed are methods of using these compounds for the treatment of diseases which can be influenced by inhibition of plasma kallikrein.
    Type: Application
    Filed: April 16, 2018
    Publication date: October 25, 2018
    Inventors: Sara FRATTINI, Iain LINGARD, Dieter Wolfgang HAMPRECHT, Remko Alexander BAKKER, Matthias ECKHARDT, Andreas GOLLNER, Joerg P. HEHN, Elke LANGKOPF, Holger WAGNER, Bernd WELLENZOHN, Dieter WIEDENMAYER
  • Publication number: 20180291030
    Abstract: The present invention encompasses compounds of formula (I) wherein the groups R1 to R7, V, W, X, Y, n and q are defined herein, their use as inhibitors of MDM2-p53 interaction, pharmaceutical compositions which contain compounds of this kind, their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases and synthetic intermediates.
    Type: Application
    Filed: June 11, 2018
    Publication date: October 11, 2018
    Inventors: Andreas GOLLNER, Christiane KOFINK, Juergen RAMHARTER, Harald WEINSTABL, Tobias WUNBERG
  • Publication number: 20180273541
    Abstract: The present invention encompasses compounds of formula (I) wherein the groups R1 to R4, R7, A, D, E, F, V, W, X, Y, n, r and q are defined in claim 1, their use as inhibitors of MDM2-p53 interaction, pharmaceutical compositions which contain compounds of this kind, their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases, and synthetic intermediates.
    Type: Application
    Filed: June 8, 2018
    Publication date: September 27, 2018
    Inventors: Andreas GOLLNER, Joachim BROEKER, Nina KERRES, Christiane KOFINK, Juergen RAMHARTER, Harald WEINSTABL, Annika GILLE, Stefan GOEPPER, Manuel HENRY, Guenther HUCHLER
  • Publication number: 20170247394
    Abstract: The present invention encompasses compounds of formula (I) wherein the groups R1 to R7, A, V, W, X, Y, n, r and q are defined in claim 1, their use as inhibitors of MDM2-p53 interaction, pharmaceutical compositions which contain compounds of this kind, their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases, and synthetic intermediates.
    Type: Application
    Filed: August 20, 2015
    Publication date: August 31, 2017
    Inventors: Juergen RAMHARTER, Joachim BROEKER, Annika GILLE, Andreas GOLLNER, Manuel HENRY, Nina KERRES, Harald WEINSTABL
  • Publication number: 20170174695
    Abstract: The present invention encompasses compounds of formula (I) wherein the groups R1 to R4, R7, A, D, E, F, V, W, X, Y, n, r and q are defined in claim 1, their use as inhibitors of MDM2-p53 interaction, pharmaceutical compositions which contain compounds of this kind, their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases, and synthetic intermediates.
    Type: Application
    Filed: October 7, 2016
    Publication date: June 22, 2017
    Inventors: Andreas GOLLNER, Joachim BROEKER, Nina KERRES, Christiane KOFINK, Juergen RAMHARTER, Harald WEINSTABL, Annika GILLE, Stefan GOEPPER, Manuel HENRY, Guenther HUCHLER
  • Publication number: 20160052938
    Abstract: The present invention encompasses compounds of formula (I) wherein the groups R1 to R7, A, V, W, X, Y, n, r and q are as defined herein, their use as inhibitors of MDM2-p53 interaction, pharmaceutical compositions which contain compounds of this kind, their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases, and synthetic intermediates.
    Type: Application
    Filed: August 20, 2015
    Publication date: February 25, 2016
    Inventors: Juergen RAMHARTER, Joachim BROEKER, Annika GILLE, Andreas GOLLNER, Manuel HENRY, Nina KERRES, Harald WEINSTABL
  • Publication number: 20160000764
    Abstract: The present invention relates to compounds of formula (I) wherein the groups R1 to R3, R7, U, V, W, X, Y, n and q are as defined herein, their use as inhibitors of MDM2-p53 interaction, pharmaceutical compositions which contain compounds of this kind, their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases and synthetic intermediates.
    Type: Application
    Filed: July 2, 2015
    Publication date: January 7, 2016
    Inventors: Harald WEINSTABL, Andreas GOLLNER, Juergen RAMHARTER, Tobias WUNBERG
  • Publication number: 20150291611
    Abstract: The present invention encompasses compounds of formula (I) wherein the groups R1 to R7, V, W, X, Y, n and q are defined herein, their use as inhibitors of MDM2-p53 interaction, pharmaceutical compositions which contain compounds of this kind, their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases and synthetic intermediates.
    Type: Application
    Filed: April 10, 2015
    Publication date: October 15, 2015
    Inventors: Andreas GOLLNER, Christiane KOFINK, Juergen RAMHARTER, Harald WEINSTABL, Tobias WUNBERG